The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A global phase III, double-blind, randomized trial of BNT327/PM8002 plus chemotherapy (chemo) compared to atezolizumab plus chemo in patients (pts) with first-line (1L) extensive-stage small cell lung cancer (ES-SCLC).
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; GlaxoSmithKline K.K.; IO Biotech; IO Biotech; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis; Sanofi/Regeneron
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi/Aventis
(OPTIONAL) Uncompensated Relationships - “Medical writing assistance for this abstract was provided by Bena Lim, PhD, CMPP, of Nucleus Global, an Inizio Company, and funded by F. Hoffmann-La Roche Ltd.” (Inst); “Medical writing assistance for this abstract was provided by Nimisha H. Bhoola, PhD, of Nucleus Global, an Inizio Company, and funded by F. Hoffmann-La Roche Ltd.” (Inst)
 
John Heymach
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - AstraZeneca; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; DAVA Pharmaceuticals; EMD Serono; Genentech/Roche; GlaxoSmithKline; Hengrui Pharmaceutical; Janssen; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Lilly (Inst); Mirati Therapeutics; Nexus Health Systems; Pneuma Respiratory; Regeneron; Sanofi/Aventis; Spectrum Pharmaceuticals; Takeda
Speakers' Bureau - DAVA Pharmaceuticals; IDEOlogy Health; MJH Life Sciences
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Mirati Therapeutics; Spectrum Pharmaceuticals; Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations; Patents pending regarding subtyping of SCLC lung cancer.
 
Kevin Franks
Employment - Genesis Cancer Care; Leeds Teaching Hospitals NHS Trust
Honoraria - AstraZeneca; Genesis Cancer Care; Roche
Consulting or Advisory Role - AstraZeneca; BioNTech SE; Lilly; Takeda
Speakers' Bureau - AstraZeneca; Roche
Travel, Accommodations, Expenses - Genesis Cancer Care; Roche; Takeda
 
Carl Gay
Honoraria - American Society for Radiation Oncology; Aptitude Health; Daiichi Sankyo Nordics; DAVA Pharmaceuticals; Peerview; Physicans' Education Resource; Targeted Oncology
Consulting or Advisory Role - Abdera Therapeutics; Amgen; AstraZeneca; Catalyst Pharmaceuticals; G1 Therapeutics; Jazz Pharmaceuticals; Monte Rosa Therapeutics; Pharmerit
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - US-20240011103-A1 MOLECULAR SUBTYPING OF SMALL CELL LUNG CANCER TO PREDICT THERAPEUTIC RESPONSES
Travel, Accommodations, Expenses - American Society for Radiation Oncology; AstraZeneca; Dava Oncology; ESMO; IASLC; MJH Live Events; Roche/Genentech
 
Vinod Ganju
Honoraria - AstraZeneca; Roche/Genentech
 
Ina Nordman
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Nicolas Girard
Employment - AstraZeneca (I)
Consulting or Advisory Role - Abbvie; AMGEN; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Ipsen; Janssen; LEO Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); MSDavenir (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; Janssen Oncology; Roche
 
Mehmet Sendur
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; MSD; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Abdi Ibrahim; Abdi Ibrahim; Amgen; Astellas Pharma; Bristol-Myers Squibb; Janssen; Novartis; Pfizer; Roche; Takeda
 
Ilhan Celik
Employment - BioNTech; Merck KGaA
Stock and Other Ownership Interests - BioNTech
Honoraria - BioNTech; Merck KGaA
Patents, Royalties, Other Intellectual Property - Merck KGaA
 
Isaac Dai
Employment - BioNTech
 
Secil Koseoglu
Employment - BioNTech SE
Stock and Other Ownership Interests - BioNTech SE; Coherus Biosciences
 
Sarita Koride
Employment - BioNTech
Stock and Other Ownership Interests - BioNTech
 
Qiong Wang
Employment - BioNTech SE
Stock and Other Ownership Interests - BioNTech SE
Travel, Accommodations, Expenses - BioNTech SE
 
Silke Günther
Employment - BioNTech
 
Guoqiang Hu
Employment - Biotheus
Stock and Other Ownership Interests - Biotheus
Patents, Royalties, Other Intellectual Property - Biotheus
 
Özlem Türeci
Employment - BioNTech
Leadership - BioNTech
Stock and Other Ownership Interests - BioNTech
Research Funding - BioNTech; HI-TRON Mainz
Patents, Royalties, Other Intellectual Property - BioNTech; HI-TRON Mainz
Travel, Accommodations, Expenses - BioNTech
Other Relationship - On the Scientific Management Board SMB) of HI-Tron; President of the Association of Cancer Immunotherapy CIMT
 
Ugur Sahin
Employment - BioNTech
Leadership - BioNTech
Stock and Other Ownership Interests - BioNTech
Research Funding - BioNTech
Patents, Royalties, Other Intellectual Property - BioNTech; Tron
Travel, Accommodations, Expenses - BioNTech
Other Relationship - Co-founder/scientific advisor at TRON; On the Scientific Management Board (SMB) of HI-TRON